LENSAR (NASDAQ:LNSR) Issues Quarterly Earnings Results

LENSAR (NASDAQ:LNSR – Get Rating) announced its quarterly earnings data on Monday. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.06, MarketWatch Earnings reports. LENSAR had a negative net margin of 56.88% and a negative return on equity of 32.96%. During the same period in the prior year, the company earned ($0.56) earnings per share.

Shares of NASDAQ:LNSR traded down $0.07 during trading on Tuesday, reaching $7.23. 1,440 shares of the company were exchanged, compared to its average volume of 11,460. The firm has a market capitalization of $79.46 million, a PE ratio of -3.46 and a beta of -0.20. The business’s fifty day simple moving average is $7.11 and its 200-day simple moving average is $6.67. LENSAR has a 12-month low of $5.50 and a 12-month high of $8.98.

A number of hedge funds have recently modified their holdings of LNSR. UBS Group AG purchased a new position in LENSAR during the third quarter valued at approximately $29,000. Geode Capital Management LLC purchased a new position in LENSAR in the third quarter worth $627,000. Finally, Millennium Management LLC purchased a new position in LENSAR in the third quarter worth $853,000. 56.02% of the stock is currently owned by institutional investors.

Separately, Zacks Investment Research raised shares of LENSAR from a “sell” rating to a “hold” rating in a research report on Tuesday, January 11th.

LENSAR Company Profile (Get Rating)

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.

Featured Stories